Hua Medicine Ltd. (HK:2552)
:2552
Want to see HK:2552 full AI Analyst Report?
2552 Stock Chart & Stats
HK$3.29
-HK$0.05(-3.62%)
At close: 4:00 PM EST
HK$3.29
-HK$0.05(-3.62%)
Day’s Range― - ―
52-Week RangeHK$2.17 - HK$4.95
Previous CloseN/A
Volume1.46M
Average Volume (3M)6.34M
Market Cap
HK$2.27B
Enterprise ValueHK$1.47B
Total Cash (Recent Filing)HK$1.09B
Total Debt (Recent Filing)HK$301.80M
Price to Earnings (P/E)1.9
Beta1.39
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.13
Shares Outstanding1,056,605,000
10 Day Avg. Volume6,422,209
30 Day Avg. Volume6,335,350
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.71
Price to Sales (P/S)5.69
P/FCF Ratio-45.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.04
Revenue Forecast (FY)HK$1.04B
Bulls Say, Bears Say
Bulls Say
Revenue & Gross Margin ImprovementSustained top-line acceleration combined with materially higher gross margin indicates stronger product economics and pricing power. Over the medium term this narrows the gap to operational breakeven, supports scalable unit economics for commercialization, and improves long-term profit potential.
Manageable Leverage & Restored EquityLower relative debt and a return to positive equity materially reduce solvency risk and increase financial flexibility. This positions the company to fund R&D, clinical programs or commercialization through internal or less costly external financing without immediate distress over the next several quarters.
Strong Revenue Growth TrendVery robust revenue growth reflects accelerating market adoption and expanding commercialization reach. Over a multi-quarter horizon strong top-line momentum supports scale benefits, improves operating leverage potential, and underpins longer-term investment in pipeline and commercial capabilities.
Bears Say
Weak Cash GenerationPersistent negative operating and free cash flow undermines internal funding for R&D and commercialization and increases reliance on external financing or equity raises. Over 2–6 months this raises dilution and execution risk if cash burn continues and capital markets are constrained.
Ongoing Operating LossesSignificant negative operating margins show the company has not achieved sustainable operational profitability despite revenue gains. Reliance on non-operating items to report net profit weakens the quality of earnings and prolongs the path to self-sustaining cash generation.
Volatile Earnings & EquityWide swings in equity and profitability signal earnings volatility and weaker predictability of results. This reduces management's ability to plan multi-quarter investments, raises counterparty and lender concerns, and increases execution and refinancing risk over the medium term.
Hua Medicine News
2552 FAQ
What was Hua Medicine Ltd.’s price range in the past 12 months?
Hua Medicine Ltd. lowest stock price was HK$2.17 and its highest was HK$4.95 in the past 12 months.
What is Hua Medicine Ltd.’s market cap?
Hua Medicine Ltd.’s market cap is HK$2.27B.
When is Hua Medicine Ltd.’s upcoming earnings report date?
Hua Medicine Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 67 days.
How were Hua Medicine Ltd.’s earnings last quarter?
Hua Medicine Ltd. released its earnings results on Mar 26, 2026. The company reported -HK$0.085 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.085.
Is Hua Medicine Ltd. overvalued?
According to Wall Street analysts Hua Medicine Ltd.’s price is currently Overvalued.
Does Hua Medicine Ltd. pay dividends?
Hua Medicine Ltd. does not currently pay dividends.
What is Hua Medicine Ltd.’s EPS estimate?
Hua Medicine Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hua Medicine Ltd. have?
Hua Medicine Ltd. has 1,056,605,000 shares outstanding.
What happened to Hua Medicine Ltd.’s price movement after its last earnings report?
Hua Medicine Ltd. reported an EPS of -HK$0.085 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.634%.
Which hedge fund is a major shareholder of Hua Medicine Ltd.?
Currently, no hedge funds are holding shares in HK:2552
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hua Medicine Ltd.
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.
2552 Company Deck
2552 Earnings Call
Q4 2026
0:00 / 0:00
Technical Analysis
HUTCHMED (China)
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
Options Prices
Currently, No data available
---